Pitvarfibrilláció: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 5
• SGLT2 5
• NLRP3 0
• BTK 3
• AMPK 0
• PI3K 0
• GIP 3
• PPAR 0
• TTR 0
• AKT 0
• PCSK9 0
• STAT3 0
• BDNF 1
• COX-2 0
• ERK 0
• HMGB1 0
• HSP90 0
• IL-6 0
• METTL3 0
• NRF2 0
• PD-1 0
• PD-L1 0
• TP53 0
• VEGF 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APOE 0
• CD40 0
• CDK4/6 0
• CFTR 0
• EGFR 0
• FTO 0
• HER3 0
• HIF-1 0
• IGF1R 0
• RUNX1 0
• SIRT1 0
• STING 0
• STK11 0
• TLR4 0
• TNF 0
• TREM2 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R00

  Emotional and biobehavioral mechanisms of parent-infant emotional synchrony

  Children's Hosp of Philadelphia· Philadelphia, Egyesült Államok· 248 999 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, Egyesült Államok· 40 326 USD awarded in fiscal year 2026· until 2028. júl.

• NIH NINR · R01

  SCH: Integrated AI and Sensing Systems for Mitigating Heart Failure Readmissions in High-Risk Groups with Obesity

  University of Pittsburgh at Pittsburgh· Pittsburgh, Egyesült Államok· 1 200 000 USD awarded in fiscal year 2026· until 2030. aug.

• NIH NIA · R43

  A Smart Remote Monitoring System for Cardiometabolic Management in Patients with Alzheimer's and Related Dementia

  Aventusoft, Llc· Boca Raton, Egyesült Államok· 500 000 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NINDS · R56

  Characterizing a Calcium Channel Causing FASP: Examining Entrainment Changes as a Mechanism for Phase Advance

  University of California, San Francisco· San Francisco, Egyesült Államok· 574 000 USD awarded in fiscal year 2026· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Olaszország· EU contribution 193 643 EUR· until 2029. aug.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular, cellular, and pharmacological characterization of a new modality of familial arrhythmia (Na-CPVT)

  Linkopings Universitet· Linkoping, Svédország· EU contribution 252 180 EUR· until 2029. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Holistic Efficient Arrhythmic Risk Twinning for Post-MI Stratification (HEART-TWIN)

  Universidad Pompeu Fabra· Barcelona, Spanyolország· EU contribution 209 915 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Svájc· EU contribution 292 119 EUR· until 2028. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Advanced Tissue Engineering, Bioprinting, and 5D Optogenetics for Arrhythmia Investigation and Treatment (OptoPrintRhythm)

  Technion - Israel Institute of Technology· Haifa, Izrael· EU contribution 3 375 000 EUR· until 2031. dec.

10 of 792 running projects, newest first. Listed amounts together: 470,8 M USD + 148,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 75
• Gene Expression Profiling 31
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 16
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 67
• Machine Learning 88
• Deep Learning 35
• Cohort Studies 221
• Genome-Wide Association Study 62

• Benchmarking metabolic surrogate indices against body mass index for left atrial diameter in atrial fibrillation: a two-cohort study.

  Front Endocrinol (Lausanne), 2026. nov.

• Ischaemic stroke and intracerebral haemorrhage in the post-acute phase after myocardial infarction: a nationwide cohort study in Sweden.

  Eur Stroke J, 2026. nov.

• Metabolic Dysfunction-Associated Steatotic Liver Disease, With and Without Increased Alcohol Intake, and Incident Atrial Fibrillation in Older Korean Adults: A Competing-Risk Cohort Study.

  Geriatr Gerontol Int, 2026. nov.

• Anticoagulation in Atrial Fibrillation With Previous Intracranial Bleeding: Competing Adverse Events in a Nationwide Cohort.

  Neurology, 2026. okt.

• Early Rhythm Control vs Usual Care After Acute Ischemic Stroke in Patients With Atrial Fibrillation.

  Neurology, 2026. okt.

• Same-Day Discharge Versus Overnight Stay After Catheter Ablation: An Observational Matched-Cohort Study on Safety and Feasibility.

  Dtsch Arztebl Int, 2026. okt.

• Latent class analysis identifies three biologically distinct phenotypes among patients undergoing endovascular thrombectomy: a derivation and temporal validation study.

  Front Neurol, 2026. okt.

• Association of preserved ratio impaired spirometry and restrictive spirometric pattern with incident atrial fibrillation: a cohort study.

  NPJ Prim Care Respir Med, 2026. okt.

• Temporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until-2022).

  Pharmacoepidemiol Drug Saf, 2026. okt.

• Anticoagulation Outcomes in Nursing Home Residents With Atrial Fibrillation and ADL Disability.

  JAMA Netw Open, 2026. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.